Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early‐stage primary biliary cholangitis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Primary biliary cholangitis (PBC) primarily targets cholangiocytes and is characterized by liver fibrosis and biliary proliferation. Activation of the secretin (Sct)/secretin receptor (SR) axis, expressed only by cholangiocytes, increases biliary proliferation, liver fibrosis, and bicarbonate secretion. We evaluated the effectiveness of SR antagonist treatment for early‐stage PBC. Male and female dominant‐negative TGF‐β receptor II (dnTGF‐βRII) (model of PBC) and wild‐type mice at 12 wk of age were treated with saline or the SR antagonist, Sec 5‐27, for 1 wk. dnTGF‐βRII mice expressed features of early‐stage PBC along with enhanced Sct/SR axis activation and Sct secretion. dnTGF‐βRII mice had increased biliary proliferation or senescence, inflammation, and liver fibrosis. In dnTGF‐βRII mice, there was increased microRNA‐125b/TGF‐β1/TGF‐β receptor 1/VEGF‐A signaling. Human early‐stage PBC patients had an increase in hepatobiliary Sct and SR expression and serum Sct levels. Increased biliary Sct/SR signaling promotes biliary and hepatic damage during early‐stage PBC.—Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Gershwin, M. E., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., Alpini, G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early‐stage primary biliary cholangitis. FASEB J. 33, 10269–10279 (2019). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067 · cited 2×
“Polarized activation of macrophages into an M1 (proinflammatory) or M2 (resolution) phenotype influences disease progression. dnTGF-bRIImicehad increased expression of CD80 and iNOS (M1) but decreased expressionofCD206 (M2) (Supplemental Fig.”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · cited 1×
“Recently, obeticholic acid was approved for the treatment of PBC after showing favorable biochemical responses (7, 8); however, this may not accurately predict long-term outcomes.”
BackgroundMacrophage Plasticity and Polarization in Liver Homeostasis and Pathology
Sica, A., Invernizzi, P., & Mantovani, A. (2014) · Hepatology · doi:10.1002/hep.26754 · Cited by 422
Self-citationRoll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417 · cited 1×
“Early-stage PBC patients have ductular reaction (37).”
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Banales, J. M., Sáez, E., Úriz, M., Sarvide, S., Urribarri, A. D., Splinter, P., Tietz Bogert, P. S., Bujanda, L., Prieto, J., Medina, J. F., et al. (2012) · Hepatology · doi:10.1002/hep.25691 · Cited by 250
Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis
Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P. M., Podda, M., Mackay, I. R., Gershwin, M. E., & Invernizzi, P. (2016) · Scientific Reports · doi:10.1038/srep25906 · Cited by 186 · cited 1×
“Recent studies have indicated that the incidence and prevalence of PBC are rising (2, 3).”
BackgroundSelf-citationSood, S., Gow, P. J., Christie, J. M., & Angus, P. W. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.064 · Cited by 140 · cited 1×
“Recent studies have indicated that the incidence and prevalence of PBC are rising (2, 3).”
Background
Cited by
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citationJin, C., Jiang, P., Zhang, Z., Han, Y., Wen, X., Zheng, L., Kuang, W., Lian, J., Yu, G., Qian, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53104-9 · Cited by 56
“The increased stimulation of the SCT/SCTR signaling was observed in early-stage PBC patients and PBC mouse model 28 .”
Cholangiokines: undervalued modulators in the hepatic microenvironment
Cai, X., Tacke, F., Guillot, A., & Liu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192840 · Cited by 40
Metadata
- Authors
- Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Eric Gershwin, M., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., & Alpini, G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2019-06-28
- Volume
- 33
- Issue
- 9
- Pages
- 10269-10279
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2954206839
- Cited by
- 47
- References
- 11
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early‐stage primary biliary cholangitis. https://app.cochat.ai/papers/10.1096/fj.201802606r
- The paper
- Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Eric Gershwin, M., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., & Alpini, G. (2019). Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early‐stage primary biliary cholangitis. The FASEB Journal. https://doi.org/10.1096/fj.201802606r
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.